Tiziana and Renaissance will partner to accelerate clinical development and potential commercial launch of nasal foralumab.

H1N1 Vaccines Market H1N1 Vaccines Market Dublin, Feb. 25, 2025 (GLOBE NEWSWIRE) -- The "H1N1 Vaccines Market Analysis by ...

In a recent publication in Cell, researchers from the National University of Singapore and collaborators have proposed using commensal bacteria in the nasal cavity as a delivery vector for precision ...

About 45% of children who receive intranasal midazolam for laceration repair do not respond to the medication and demonstrate ...

Alternative dosing routes, such as rectal and intranasal (IN) routes, have been suggested as options for oral or intravenous administration. Rhinitis and pharmacological agents used for treatment ...

Long COVID is a complex and often debilitating complication following COVID-19 infection. It affects millions worldwide, presenting with symptoms such as persistent fatigue, cognitive impairment ...

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and ...

Oragenics (OGEN) announced its participation at the Emergencies in Medicine Conference, where Dr. James Kelly, Chief Medical Officer and ...

has entered into a product development services agreement with Renaissance Lakewood LLC to enhance and scale up the formulation of its lead candidate, intranasal foralumab, a fully human anti-CD3 ...

The following is a summary of “Prophylaxis for renal patients at risk of COVID-19 infection: results from the intranasal niclosamide randomised, double blinded, placebo controlled arm of the PROTECT-V ...

Exploring alternative vaccine delivery systems could increase accessibility and encourage those who fear needles to receive ...

It's allergy season in Arizona. Here's everything to know, including what is causing your allergies, common seasonal allergy ...